Hang Thi Nguyen

Ms. Hang Thi Nguyen

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 March 2021 in Antibiotics
Verified
Journal Article
Open access
PDF file
HNHang Thi Nguyen
Hang Thi Nguyen
LOLisa A. O’donovan
Lisa A. O’donovan
Henrietta VenterHenrietta Venter
Henrietta Venter
CRCecilia C. Russell
Cecilia C. Russell
AMAdam Mccluskey
Adam Mccluskey
AOAbiodun D. Ogunniyi
Abiodun D. Ogunniyi
In this study, we optimized and compared different transmission electron microscopy (TEM) methods to visualize changes to Gram-negative bacterial morphology induced by treatment with a robenidine analogue (NCL195) and colistin combination. Aldehyde-fixed bacterial cells (untreated, treated with colistin or NCL195 + colistin) were prepared using conventional TEM methods and compared with ultrathin Tokuyasu cryo-sections. The results of this study indicate superiority of ultrathin cryo-sections in visualizing the membrane ultrastructure of Escherichia coli and Pseudomonas aeruginosa, with a clear delineation of the outer and inner membrane as well as the peptidoglycan layer. We suggest that the use of ultrathin cryo-sectioning can be used to better visualize and understand drug interaction mechanisms on the bacterial cell membrane.

4 August 2020 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
HPHongfei Pi
Hongfei Pi
HNHang Thi Nguyen
Hang Thi Nguyen
Henrietta VenterHenrietta Venter
Henrietta Venter
ABAlexandra R. Boileau
Alexandra R. Boileau
LWLucy Woolford
Lucy Woolford
AOAbiodun D. Ogunniyi
Abiodun D. Ogunniyi
Multidrug-resistant (MDR) pathogens, particularly the ESKAPE group (Enterococcus faecalis/faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Escherichia coli, and Enterobacter spp.), have become a public health threat worldwide. Development of new antimicrobial classes and the use of drugs in combination are potential strategies to treat MDR ESKAPE pathogen infections and promote optimal antimicrobial stewardship. Here, the in vitro antimicrobial activity of robenidine analog NCL195 alone or in combination with different concentrations of three outer membrane permeabilizers [ethylenediaminetetraacetic acid (EDTA), polymyxin B nonapeptide (PMBN), and polymyxin B (PMB)] was further evaluated against clinical isolates and reference strains of key Gram-negative bacteria. NCL195 alone was bactericidal against Neisseria meningitidis and Neisseria gonorrhoeae (MIC/MBC = 32 μg/mL) and demonstrated synergistic activity against P. aeruginosa, E. coli, K. pneumoniae, and Enterobacter spp. strains in the presence of subinhibitory concentrations of EDTA, PMBN, or PMB. The additive and/or synergistic effects of NCL195 in combination with EDTA, PMBN, or PMB are promising developments for a new chemical class scaffold to treat Gram-negative infections. Tokuyasu cryo ultramicrotomy was used to visualize the effect of NCL195 on bioluminescent S. aureus membrane morphology. Additionally, NCL195’s favorable pharmacokinetic and pharmacodynamic profile was further explored in in vivo safety studies in mice and preliminary efficacy studies against Gram-positive bacteria. Mice administered two doses of NCL195 (50 mg/kg) by the intraperitoneal (IP) route 4 h apart showed no adverse clinical effects and no observable histological effects in major organs. In bioluminescent Streptococcus pneumoniae and S. aureus murine sepsis challenge models, mice that received two 50 mg/kg doses of NCL195 4 or 6 h apart exhibited significantly reduced bacterial loads and longer survival times than untreated mice. However, further medicinal chemistry and pharmaceutical development to improve potency, solubility, and selectivity is required before efficacy testing in Gram-negative infection models.

10 August 2021 in Microorganisms
Verified
Journal Article
Open access
PDF file
HPHongfei Pi
Hongfei Pi
AOAbiodun D. Ogunniyi
Abiodun D. Ogunniyi
BSBhumi Savaliya
Bhumi Savaliya
HNHang Thi Nguyen
Hang Thi Nguyen
SPStephen Page
Stephen Page
DTDarren Trott
Darren Trott
One approach to combat the increasing incidence of multidrug-resistant (MDR) bacterial pathogens involves repurposing existing compounds with known safety and development pathways as new antibacterial classes with potentially novel mechanisms of action. Here, triclabendazole (TCBZ), a drug originally developed to treat Fasciola hepatica (liver fluke) in sheep and cattle, and later in humans, was evaluated as an antibacterial alone or in combination with sub-inhibitory concentrations of polymyxin B (PMB) against clinical isolates and reference strains of key Gram-positive and Gram-negative bacteria. We show for the first time that in vitro, TCBZ selectively kills methicillin-sensitive and methicillin-resistant Staphylococcus aureus and Staphylococcus pseudintermedius at a minimum inhibitory concentration (MIC) range of 2–4 µg/mL, and vancomycin-resistant enterococci at a MIC range of 4–8 µg/mL. TCBZ also inhibited key Gram-negative bacteria in the presence of sub-inhibitory concentrations of PMB, returning MIC90 values of 1 µg/mL for Escherichia coli, 8 µg/mL for Klebsiella pneumoniae, 2 µg/mL for Acinetobacter baumannii and 4 µg/mL for Pseudomonasaeruginosa. Interestingly, TCBZ was found to be bacteriostatic against intracellular S. aureus but bactericidal against intracellular S. pseudintermedius. Additionally, TCBZ’s favourable pharmacokinetic (PK) and pharmacodynamic (PD) profile was further explored by in vivo safety and efficacy studies using a bioluminescent mouse model of S. aureus sepsis. We show that repeated four-hourly oral treatment of mice with 50 mg/kg TCBZ after systemic S. aureus challenge resulted in a significant reduction in S. aureus populations in the blood to 18 h post-infection (compared to untreated mice) but did not clear the bacterial infection from the bloodstream, consistent with in vivo bacteriostatic activity. These results indicate that additional pharmaceutical development of TCBZ may enhance its PK/PD, allowing it to be an appropriate candidate for the treatment of serious MDR bacterial pathogens.

8 January 2021 in Organic & Biomolecular Chemistry
Verified
Journal Article
Closed access
PDF file
MMMahmud T. Morshed
Mahmud T. Morshed
HNHang Thi Nguyen
Hang Thi Nguyen
DVDaniel Vuong
Daniel Vuong
ACAndrew Crombie
Andrew Crombie
ELErnest Lacey
Ernest Lacey
Andrew PiggottAndrew Piggott
Andrew Piggott
In this study, we report the semisynthesis and in vitro biological evaluation of thirty-four derivatives of the fungal depsidone antibiotic, unguinol. Initially, the semisynthetic modifications were focused on the two free hydroxy groups (3-OH and 8-OH), the three free aromatic positions (C-2, C-4 and C-7), the butenyl side chain and the depsidone ester linkage. Fifteen first-generation unguinol analogues were synthesised and screened against a panel of bacteria, fungi and mammalian cells to formulate a basic structure activity relationship (SAR) for the unguinol pharmacophore. Based on the SAR studies, we synthesised a further nineteen second-generation analogues, specifically aimed at improving the antibacterial potency of the pharmacophore. In vitro antibacterial activity testing of these compounds revealed that 3-O-(2-fluorobenzyl)unguinol and 3-O-(2,4-difluorobenzyl)unguinol showed potent activity against both methicillin-susceptible and methicillin-resistant Staphylococcus aureus (MIC 0.25–1 μg mL−1) and are promising candidates for further development in vivo.

6 January 2022 in Antibiotics
Verified
Journal Article
Open access
PDF file
HNHang Thi Nguyen
Hang Thi Nguyen
Henrietta VenterHenrietta Venter
Henrietta Venter
LWLucy Woolford
Lucy Woolford
KYKelly Young
Kelly Young
AMAdam Mccluskey
Adam Mccluskey
AOAbiodun D. Ogunniyi
Abiodun D. Ogunniyi
In this study, we investigated the potential of an analogue of robenidine (NCL179) to expand its chemical diversity for the treatment of multidrug-resistant (MDR) bacterial infections. We show that NCL179 exhibits potent bactericidal activity, returning minimum inhibitory concentration/minimum bactericidal concentrations (MICs/MBCs) of 1–2 µg/mL against methicillin-resistant Staphylococcus aureus, MICs/MBCs of 1–2 µg/mL against methicillin-resistant S. pseudintermedius and MICs/MBCs of 2–4 µg/mL against vancomycin-resistant enterococci. NCL179 showed synergistic activity against clinical isolates and reference strains of Acinetobacter baumannii, Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa in the presence of sub-inhibitory concentrations of colistin, whereas NCL179 alone had no activity. Mice given oral NCL179 at 10 mg/kg and 50 mg/kg (4 × doses, 4 h apart) showed no adverse clinical effects and no observable histological effects in any of the organs examined. In a bioluminescent S. aureus sepsis challenge model, mice that received four oral doses of NCL179 at 50 mg/kg at 4 h intervals exhibited significantly reduced bacterial loads, longer survival times and higher overall survival rates than the vehicle-only treated mice. These results support NCL179 as a valid candidate for further development to treat MDR bacterial infections as a stand-alone antibiotic or in combination with existing antibiotic classes.

23 October 2025 in Microbiologyopen
Verified
Journal Article
Open access
HNHang Thi Nguyen
Hang Thi Nguyen
JPJiratchaya Puangseree
Jiratchaya Puangseree
TNTien Thanh Nguyen
Tien Thanh Nguyen
MNManh Tuong Nguyen
Manh Tuong Nguyen
CLChristopher Leigh
Christopher Leigh
AOAbiodun D. Ogunniyi
Abiodun D. Ogunniyi
Multidrug‐resistant (MDR) bacterial infections constitute one of the top global public health threats. This study investigated the potential of gallium liquid metal nanoparticles (GaLM NPs) as a new agent against MDR pathogens. GaLM NPs was bactericidal against methicillin‐resistant Staphylococcus aureus (MRSA) isolates and a vancomycin‐intermediate S. aureus reference strain (minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) values between 39 and 156 μg/mL). The bactericidal activity of GaLM NPs was supported by transmission electron microscopy showing marked ultrastructural changes in the cell envelope of MRSA USA300. GaLM NPs were bacteriostatic against selected Gram‐negative ( Acinetobacter baumannii , Pseudomonas aeruginosa and Klebsiella pneumoniae ) reference strains and isolates (MICs between 39 and 625 μg/mL). Furthermore, GaLM NPs demonstrated additive and bacteriostatic activity when combined with sub‐inhibitory concentrations of colistin against P. aeruginosa isolates. Additionally, GaLM NPs showed anti‐biofilm activity against MRSA USA300 (minimum biofilm eradication concentration of 625 μg/mL); morphology changes of GaLM NPs‐treated cells was demonstrated by scanning electron microscopy. Finally, GaLM NPs was safe to human epidermal keratinocyte cell line at 1024 µg/mL (6.5 × MIC). We conclude that GaLM NPs warrant further exploration for the effective treatment of Gram‐positive or Gram‐negative infections both alone and in combination with antimicrobial drugs.